



Bibliography

Benefit Status

Health Canada special access programme [Internet]. Ottawa: Health Canada; 2018 [cited 2020 Jan 23]. Available from: <https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html>

Badry N. BC Cancer Drug Manual [Internet]. Vancouver: BC Cancer [cited 2018 Jun 06]. Available from: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-drug-manual>

BC Cancer Compassionate Access Program [Internet]. Vancouver: BC Cancer [cited 2020 Jan 23]. Available from: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy>

BC Cancer Benefit Drug List [Internet]. Vancouver: BC Cancer [cited 2020 Jan 23]. Available from: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy>

Cancer Drug Dosing and Scheduling of Treatment

Wallach JB. Hepatobiliary disease and diseases of the pancreas. In: Wallach JB, editor. Interpretation of diagnostic tests. 7th ed. Philadelphia (PA):Lippincott Williams & Wilkins; 2000. p. 199–261.

Balmer C, Finley RS. Systemic toxicity. In: Finley RS, Balmer C, editors. Concepts in oncology therapeutics. Bethesda (MD): American Society of Health-System Pharmacists; 1998. p. 99–120.

BC Cancer Policy III-10 Systemic Therapy Delivery Process [Internet]. Vancouver: BC Cancer [cited 2020 Jan 23]. Available from: <http://shop.healthcarebc.ca/phsa/BCCancer/Systemic%20Therapy/70005.pdf>

BC Cancer Policy III-40 Systemic Therapy Treatments [Internet]. Vancouver: BC Cancer [cited 2020 Jan 23]. Available from: <http://shop.healthcarebc.ca/phsa/BCCancer/Systemic%20Therapy/70005.pdf>



BC Cancer Policy III-45 Compassionate Access Program [Internet]. Vancouver: BC Cancer [cited 2020 Jan 23]. Available from: <http://shop.healthcarebc.ca/phsa/BCCancer/Systemic%20Therapy/70005.pdf>

Calvert AH. Dose optimisation of CARBOplatin in adults. *Anticancer Res* 1994;14:2273–8

Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. CARBOplatin dosage: prospective evaluation of a simple formula based on renal function. *J Clin Oncol* 1989;7:1748–56.

Cole D. Background and controversies in dosing and adjustment of chemotherapy agents. Presentation at the 2002 BC Cancer Agency Annual Conference; 2002 Nov 30. Not published.

Badry N. BC Cancer Drug Manual [Internet]. Vancouver: BC Cancer [cited 2018 Jul 11]. Available from: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-drug-manual>

DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. *Arch Intern Med* 1916;17:863–71.

Egorin MJ, Jodrell DI. Utility of individualized CARBOplatin dosing alone and in combination regimens. *Semin Oncol* 1992;19(1 Suppl 2):132–8.

Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, et al. Pharmacokinetics and dosage reduction of cisdiammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. *Cancer Res* 1984;44:5432–8.

Farkas P, Hyde D. Liver and gastroenterology tests. In: Traub SL, editor. *Basic skills in interpreting laboratory data*. 2nd ed. Bethesda (MD):American Society of Health-System Pharmacists; 1996. p. 213–44.

Finley RS, Lindley CM, editors. Neoplastic disorders. In: Young LY, Koda-Kimble MA, editors. *Applied therapeutics: the clinical use of drugs*. 6th ed. Vancouver (WA): Applied Therapeutics; 1995. p.90-1–94-25.

Gehan EA, George SL. Estimation of human body surface area from height and weight. *Cancer Chemother Rep* 1970;54:225–35.

Gelman RS, Tormey DC, Betensky R, Mansour EG, Falkson HC, Falkson G, et



al. Actual versus ideal weight in the calculation of surface area: effects on dose of 11 chemotherapy agents. *Cancer Treat Rep* 1987;71:907–11.

Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children and adults. *J Pediatr* 1978; 93: 62–6.

Johnson SW, Stevenson JP, O'Dwyer PJ. Pharmacology of cancer chemotherapy: CISplatin and its analogues. In: DeVita Jr. VT, Hellman S, Rosenberg SA (editors). *Cancer principles and practice of oncology*. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2001. p. 376–89.

Lam TK, Leung DT. More on simplified calculation of body-surface area. *N Engl J Med* 1988;318:1130.

Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, editors. *Wintrobe's clinical hematology*. vol. 1. 9th ed. Philadelphia (PA): Lea & Febiger; 1993.

Livingston EH, Lee S. Body surface area prediction in normal-weight and obese patients. *Am J Physiol Endocrinol Metab* 2001;281:E586–91.

Moore M. Glomerular Filtration Rate (GFR) - By Renogram, Cockcroft-Gault or MDRD? BC Cancer Systemic Therapy Update [Internet] Vancouver: BC Cancer; November 2005;8(11):1-2. Available from <http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update>

Mosteller RD. Simplified calculation of body-surface area. *N Engl J Med* 1987;317:1098.

Perry MC. Hepatotoxicity. In: Perry MC, editor. *The chemotherapy sourcebook*. Baltimore (MD): Williams & Wilkins; 1992. p. 635–47.

Yee GC, editor. Oncologic disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors for 3rd ed. *Pharmacotherapy: a pathophysiologic approach*. 3rd ed. Stamford (CT): Appleton & Lange; 1997. p. 49–76.

Young LY, Holland EG. Interpretation of clinical laboratory tests. In Young LY, Koda-Kimble MA, editors. *Applied therapeutics: the clinical use of drugs*. 6th ed. Vancouver (WA): Applied Therapeutics; 1995. p.4-1–4-20.

Laboratory Test Interpretation

Life Labs reference ranges section (HCP – reference ranges page) [Internet] Burnaby: Life Labs; 2019 [cited 2020 Jan 23]. Available from: <https://www.lifelabs.com/page-section/reference-ranges-section-hcp-reference-ranges-page/>

HealthLinkBC. Understanding lab test results [Internet] Victoria: Government of BC; 1995 [cited 2020 Jan 23]. Available from: <https://www.healthlinkbc.ca/health-topics/zp3409>

Lab Tests online [Internet]. Washington: American Association for clinical chemistry [cited 2020 Jan 23]. Available from: <https://labtestsonline.org/for-health-professionals>

Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. *Endocr Relat Cancer* [Internet] 2014 [cited 2018 Aug 21]; 21(2):371–381. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573438/>

Takaya K, Sonoda M, Fuchigami A, et al. Isolated Adrenocorticotrophic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. *Intern Med* [Internet]. 2017 [cited 2018 Aug 21]; 56(18):2463–2469. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643175/>

Haanen JB, Carbone F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* [Internet] 2017 [cited 2018 Aug 21]; 28(suppl 4): iv119–iv142. Available from: https://academic.oup.com/annonc/article/28/suppl_4/iv119/3958159

Friedman C, Clark V, Raikhel AV, et al. Thinking critically about classifying adverse events: Incidence of pancreatitis in patients treated with Nivolumab + Ipilimumab. *JNCI: Journal of the National Cancer Institute* [Internet] 2017 [cited 2018 Aug 21]; 109(4):djw260. Available from: <https://academic.oup.com/jnci/article/109/4/djw260/2898135>

Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. *Transl Lung Cancer Res.* [Internet]

2015 [cited 2018 Aug 22];4(5):560–575. Available from:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630514/>

Canadian Cancer Society. Tumor lysis syndrome [Internet]. Toronto: Canadian Cancer Society [cited 2018 Aug 22]. Available from:
<http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/managing-side-effects/tumour-lysis-syndrome/?region=on>

Mirrakhimov AE, Voore P, Khan M, et al. Tumor lysis syndrome: A clinical review. *World J Crit Care Med* [Internet] 2015 [cited 2018 Aug 22];4(2):130–138. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411564/>

Brown JE, Cook RJ, Lipton A, et al. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. *Clin Cancer Res* [Internet] 2012 [cited 2018 Aug 22]; 18:6348–55. Available from:
<https://www.ncbi.nlm.nih.gov/pubmed/22952345>

BC Cancer Protocol Summary Guidelines for the use of Erythropoiesis-Stimulating Agents (ESAs) in patients with cancer (SCESA) [Internet] Vancouver: BC Cancer [cited 2018 Aug 28]. Available from:
<http://www.bccancer.bc.ca/health-professionals/clinical-resources/chemotherapy-protocols/supportive-care>

BC Cancer empiric treatment of febrile neutropenia (Solid Tumour or lymphoma) [Internet] Vancouver: BC Cancer [cited 2018 Aug 28]. Available from:
<http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-management-guidelines/supportive-care/febrile-neutropenia>

BC Cancer LYRITUX Protocol [Internet] Vancouver: BC Cancer [cited 2018 Aug 28]. Available from: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/chemotherapy-protocols/lymphoma-myeloma>

BC Cancer ritUXimab monograph for health professionals [Internet] Vancouver: BC Cancer [cited 2018 Aug 28]. Available from:
<http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-drug-manual/drug-index#r-content>

BC Cancer. CARBOplatin dosing based on serum creatinine. Systemic Therapy Update [Internet] 2011 [cited 2018 Aug 28];14(4):1-2. Available from
<http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic->



therapy/systemic-therapy-update

Breslin S. Cytokine-release syndrome: overview and nursing implications. *Clin.J.Oncol.Nurs* [Internet] 2007 [cited 2018 Aug 28];11(Suppl 1):37-42. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/17471824>

Collier J, Bassendine M. How to respond to abnormal liver function tests. *Clin.Med.* 2002 Sep-Oct;2(5):406-409.

Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. *Oncology (Williston Park)* [Internet] 2005 [cited 2018 Aug 28];19(8):1057-63; discussion 1063-4, 1069. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/16131047>

King PD, Perry MC. Hepatotoxicity of chemotherapy. *Oncologist* 2001;6(2):162-176.

Moore M. Glomerular Filtration Rate (GFR) - By Renogram, Cockcroft-Gault or MDRD? BC Cancer Systemic Therapy Update [Internet] Vancouver: BC Cancer; November 2005;8(11):1-2. Available from <http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update>

Superfin D, Iannucci AA, Davies AM. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. *Oncologist* 2007 Sep;12(9):1070-1083.

Tefferi A. Approach to the patient with thrombocytosis. In: Landaw S, Leung L, editors. UpToDate ed. Waltham, MA; 2019

Parenteral Drug Delivery

Balmer C, Finley RS. Pharmacy practice issues in oncology. Concepts in oncology therapeutics. 2nd ed. Bethesda(MD): American Society of Health-System Pharmacists; 1998. p. 357–88.

BC Cancer Nursing Practice Reference C-252: Chemotherapeutic Agents, Administration of [Internet] Vancouver: BC Cancer [cited 2018 Sep 04]. Available from: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/nursing/nursing-practice-references>.

Badry N. BC Cancer Drug Manual [Internet]. Vancouver: BC Cancer [cited 2018 Sep 12]. Available from: <http://www.bccancer.bc.ca/health-professionals/clinical->



[resources/cancer-drug-manual](#)

Perry M. Drug administration. Chemotherapy source book. Baltimore (MD): Williams & Wilkins; 1992. p. 756–883.

Fraser health authority vascular access regional shared work team; Fraser health central venous catheters in adult patients self learning module – version 7. Surrey, BC: Fraser Health Authority; 2011 July. Available from: <http://www.fraserhealth.ca/media/CentralVenousCatheters.pdf>.

Finley RS, editor. Administration of cancer chemotherapy. Concepts in oncology therapeutics. 2nd ed. Bethesda (MD): American Society of Health-System Pharmacists; 1998. p. 173–96.

Individual drug monographs. In: Repchinsky C, editor. Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association. 2003.

McEvoy GK, editor. American Hospital Formulary Services. Bethesda(MD): American Society of Health-System Pharmacists; 2003.

Chow L, Moore M, BCCA Division of Pharmacy. Aseptic and Safe Preparation of Cytotoxic Drugs - Procedures and Checklists. Vancouver, BC: BC Cancer Agency; 1995

Trissel LA, editor. Handbook on injectable drugs. 12th ed. Bethesda (MD): American Society of Health-System Pharmacists; 2003.

USP DI Volume I: Drug information for the health care professional. 20th ed. Englewood (CO): Micromedex; 2000.

Chemotherapy Toxicity Issues

Balmer C, editor. Major organ toxicity. Concepts in oncology therapeutics. 2nd ed. Bethesda (MD): American Society of Health System-Pharmacists; 1998. p. 121–46.

BC Cancer Policy III-20 Chemotherapy Extravasation [Internet]. Vancouver: BC Cancer [cited 2020 Jan 23]. Available from: <http://shop.healthcarebc.ca/phsa/BCCancer/Systemic%20Therapy/70005.pdf>

BC Cancer Systemic Therapy Update [Internet] 2002 [cited 2020 Jan 23];5(6). Available from <http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update>.

Bleomycin monograph. In: Repchinsky C, editor. Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association; 2003.

Calabresi P, Chabner BA. Antineoplastic agents. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. Philadelphia (PA): McGraw-Hill; 2001. p.1389–1459.

Badry N. BC Cancer Drug Manual [Internet]. Vancouver: BC Cancer [cited 2018 Sep 17]. Available from: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-drug-manual>

DeConti RC. Carcinomas of head and neck. In: Skeel RT, editor. Handbook of cancer chemotherapy. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 1999. p. 177–97.

Dorr RT, Von Hoff DD. Part III: Drug monographs. In: Dorr RT, Von Hoff, DD, editors. Cancer chemotherapy handbook. 2nd ed. Norwalk(CT): Appleton & Lange; 1994. p. 129–978.

Finley RS, Lindley CM, editors. Neoplastic disorders. In: Young LY, Koda-Kimble MA, editors. Applied therapeutics: the clinical use of drugs. 6th ed. Vancouver (WA): Applied Therapeutics; 1995. p.90-1–94-25.

Hrushesky WJM. Circadian timing and toxicity. In: Perry M, editor. Chemotherapy source book. Baltimore (MD): Williams & Wilkins; 1992. p.165–212.

Management of drug toxicity. In: Perry M, editor. Chemotherapy sourcebook. Baltimore (MD): Williams & Wilkins; 1992. p. 498–753.

Part 1: Drug monographs — antineoplastics, chemoprotectants and immunosuppressants. In: Anderson PO, Knoben JE, editors. Handbook of clinical drug data. 8th ed. Stamford (CT): Appleton & Lange; 1997. p.157–226.

Patterson WP, Reams GP. Renal abnormalities. In: Perry M, editor. Chemotherapy source book. Baltimore (MD): Williams & Wilkins; 1992. p.648–65.



Skeel RT. Antineoplastic drugs and biologic response modifiers. In: Skeel RT, editor. Handbook of cancer chemotherapy. 5th ed. Philadelphia (PA):Lippincott Williams & Wilkins; 1999. p. 63–143.

Protocol-Related Supportive Care

Anderson PO, Knoben JE, editors. Handbook of clinical drug data. 9th ed. Stamford (CT): Appleton & Lange; 1999.

BC Cancer Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults (SCNAUSEA) [Internet]. Vancouver: BC Cancer [cited 2020 Jan 23]. Available from: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/chemotherapy-protocols/supportive-care>

Ferrier L, Oliver J. Drug Update: Aprepitant for Highly Emetogenic Chemotherapy. BC Cancer Systemic Therapy Update [Internet] 2008 [cited 2018 Sep 05];11(3). Available from: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update>

Haselberger MB, Schwinghammer TL. Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann Pharmacother 1995;29:918–21.

Levine MN, Bramwell V, Pritchard K, et al. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. Eur J Cancer 1992;29A(1):37–43.

McCormack J, editor. Drug therapy decision making guide. Philadelphia(PA): WB Saunders; 1996.

McEvoy GK, editor. American Hospital Formulary Services. Bethesda(MD): American Society of Health-System Pharmacists; 2003.

Markman M, Kennedy A, Webster K, et al. Use of low-dose oral prednisone to prevent PACLitaxel-induced arthralgias and myalgias. Gynecol Oncol 1999;72:100–1.

Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/ leucovorin: summary findings of an independent panel. J Clin Oncol 2001;18:3801–7.



Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2000;343:905–14.

Schoenike SE, Dana WJ. Ifosfamide and mesna. *Clin Pharm* 1990;9:179–91.

Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2015 Oct 1;33(28):3199-212.

Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. *BMJ* 2001;323(7303):16–21.

Aprepitant: Drug Information in UpToDate [Internet] Waltham: UpToDate [cited 2010 June 9]. Available from: <http://www.uptodate.com/home/index.html>

van Deventer H, Bernard S. Use of gabapentin to treat taxane-induced myalgias. *J Clin Oncol* 1999;17:434–5.

Dar Santos A, Waignein S, de Lemos M. Drug Update: Pharmacare coverage for Netupitant/Palonosteron. *BC Cancer Systemic Therapy Update* [Internet] 2020 [cited 2020 Jan 23];23(1). Available from: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update>